Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-10

Study Completion Date

2017-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

NCT06382168

Leukemia, Myeloid, Acute

RECRUITING PHASE1/PHASE2

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia Adult Acute Monocytic Leukemia +14 more

COMPLETED PHASE3

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

NCT03298516

Leukemia, Myeloid, Acute

COMPLETED PHASE1

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245

Relapsed Acute Lymphoblastic Leukemia (ALL) Refractory Acute Lymphoblastic Leukemia (ALL) Relapsed Acute Myelogenous Leukemia (AML) +6 more

ACTIVE_NOT_RECRUITING PHASE1

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02642965

Acute Myeloid Leukemia Post Cytotoxic Therapy Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will determine the safety and efficacy of DFP-10917 in patients with AML or ALL. The Phase I dose-escalation portion of the study will determine the highest tolerable dose and regimen (7 or 14 day continuous infusion) based on safety data in patients with refractory or relapsed AML or ALL. The phase II portion will investigate the safety and efficacy of DFP-10917, at the dose and regimen to be determined in the Phase I portion, in patients with refractory or relapsed AML.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Acute Lymphocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DFP-10917

1. 7-day continuous infusion (in the vein): Starting dose 4 mg/m\^2
2. 14-day continuous infusion (in the vein): Starting dose 10 mg/m\^2
3. Phase II Only: 6 mg/m\^2 for the 14-day continuous infusion (in the vein)

Group Type EXPERIMENTAL

DFP-10917

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DFP-10917

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must have pathologically-confirmed acute leukemia, refractory or relapsed after standard therapy for the disease or for which conventional systemic chemotherapy is not reliably effective or no effective therapy is available Phase II Only: Patient must have histologically or pathologically confirmed diagnosis of AML based on WHO classification that is refractory after standard therapy, or for which conventional systemic chemotherapy is not reliably effective, or no effective therapy is available. Patients aged 60 years or older with newly diagnosed AML who are not eligible for, or who refuse, standard care are also eligible.
2. Aged ≥ 18 years.
3. ECOG Performance Status of 0, 1 or 2.
4. Adequate clinical laboratory values (i.e., plasma creatinine \<= 1.5 x upper limit of normal (ULN) for the institution, bilirubin \<=1.5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST) \<= 2.5 x ULN).
5. Absence of CNS involvement by leukemia.
6. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.
7. Signed informed consent prior to the start of any study specific procedures.
8. Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.

Exclusion Criteria

1. The interval from prior treatment to time of study drug administration is \< 2 weeks for cytotoxic agents or \< 5 half-lives for noncytotoxic agents. Exceptions: Use of hydroxyurea is allowed before the start of study and may be administered up to day 5 of the first cycle.
2. Any \>grade 1 persistent clinically significant toxicities from prior chemotherapy.
3. Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
4. Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.
5. A pregnant or lactating woman.
6. Current malignancies of another type. Exceptions: Patients may participate if they have previously treated and currently controlled prostate cancer, adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.
7. Patient has acute promyelocytic leukemia (APL).
8. Patients with known HIV, HBV or HCV infection (note: testing for these infections is not required).
9. Documented or known clinically significant bleeding disorder.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No